Cybersecurity has changed dramatically over the past 10,000 days. In this episode of Threat Vector, host David Moulton speaks with Haider Pasha, Chief Security Officer for EMEA & LATAM at Palo Alto ...

RP-L102 is based on stem cells harvested from FA patients’ peripheral blood that are modified with a lentiviral vector to contain ... with the disease. The EMA has started its review of RP ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The EMEA Masters 2025 Winter season is kicking off and fans are excited to see whether new stars will shine through and possibly make it to the LEC in the next competitive year. Previously known as EU ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

Buckinghamshire Council harnesses low Earth orbit technology to serve the most remote areas of the county with ultrafast broadband Continue Reading ...

The rise of DeepSeek has prompted the usual well-documented concerns around AI, but also raised worries about its potential links to the Chinese state. The Security Think Tank considers the steps ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

The volume of data breaches grew 6% year-on-year (YoY) in 2024, fueled by double-digit increases in ransomware, compromised ...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal ...